tetano
Editor, Senior Moderator
J Gen Virol
. 2021 Nov;102(11).
doi: 10.1099/jgv.0.001684.
Infection in asymptomatic carriers of SARS-CoV-2 can interfere with the achievement of robust immunity on a population scale
Kelvinson Viana[SUP] 1 [/SUP], Luis Zarpelon[SUP] 1 [/SUP], Andre Leandro[SUP] 2 [/SUP], Maria Terencio[SUP] 1 [/SUP], Renata Lopes[SUP] 2 [/SUP], Caroline Martins[SUP] 2 [/SUP], Isaak Silva[SUP] 2 [/SUP], Alessandra Sibim[SUP] 1 [/SUP], Fábio Marques[SUP] 3 [/SUP], Rafael da Silva[SUP] 3 [/SUP], Açucena Rivas[SUP] 1 [/SUP], Adrieli Souza[SUP] 1 [/SUP], Angelo Dos-Santos[SUP] 1 [/SUP], Sara Torres[SUP] 1 [/SUP], Maria Garcia[SUP] 1 [/SUP], Rodolfo Giunchetti[SUP] 4 [/SUP], Wagner Chiba-de-Castro[SUP] 1 [/SUP]
Affiliations
Abstract
The severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) continues to spread worldwide as a severe pandemic, and a significant portion of the infected population may remain asymptomatic. Given this, five surveys were carried out between May and September 2020 with a total of 3585 volunteers in the municipality of Foz do Iguaçu, State of Paraná, a triple border region between Brazil/Argentina/Paraguay. Five months after the first infection, volunteers were re-analysed for the production of IgG anti-Spike and anti-RBD-Spike, in addition to analyses of cellular immunity. Seroconversion rates ranged from 4.4 % to a peak of 37.21 % followed by a reduction in seroconversion to 21.1 % in September, indicating that 25 % of the population lost their circulating anti-SARS-CoV-2 antibodies 3 months after infection. Analyses after 5 months of infection showed that only 17.2 % of people still had anti-RBD-Spike antibodies, however, most volunteers had some degree of cellular immune response. The strategy of letting people become naturally infected with SARS-CoV-2 to achieve herd immunity is flawed, and the first contact with the virus may not generate enough immunogenic stimulus to prevent a possible second infection.
Keywords: SARS-CoV-2; cell immunity; herd immunity; humoral immunity.
. 2021 Nov;102(11).
doi: 10.1099/jgv.0.001684.
Infection in asymptomatic carriers of SARS-CoV-2 can interfere with the achievement of robust immunity on a population scale
Kelvinson Viana[SUP] 1 [/SUP], Luis Zarpelon[SUP] 1 [/SUP], Andre Leandro[SUP] 2 [/SUP], Maria Terencio[SUP] 1 [/SUP], Renata Lopes[SUP] 2 [/SUP], Caroline Martins[SUP] 2 [/SUP], Isaak Silva[SUP] 2 [/SUP], Alessandra Sibim[SUP] 1 [/SUP], Fábio Marques[SUP] 3 [/SUP], Rafael da Silva[SUP] 3 [/SUP], Açucena Rivas[SUP] 1 [/SUP], Adrieli Souza[SUP] 1 [/SUP], Angelo Dos-Santos[SUP] 1 [/SUP], Sara Torres[SUP] 1 [/SUP], Maria Garcia[SUP] 1 [/SUP], Rodolfo Giunchetti[SUP] 4 [/SUP], Wagner Chiba-de-Castro[SUP] 1 [/SUP]
Affiliations
- PMID: 34788210
- DOI: 10.1099/jgv.0.001684
Abstract
The severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) continues to spread worldwide as a severe pandemic, and a significant portion of the infected population may remain asymptomatic. Given this, five surveys were carried out between May and September 2020 with a total of 3585 volunteers in the municipality of Foz do Iguaçu, State of Paraná, a triple border region between Brazil/Argentina/Paraguay. Five months after the first infection, volunteers were re-analysed for the production of IgG anti-Spike and anti-RBD-Spike, in addition to analyses of cellular immunity. Seroconversion rates ranged from 4.4 % to a peak of 37.21 % followed by a reduction in seroconversion to 21.1 % in September, indicating that 25 % of the population lost their circulating anti-SARS-CoV-2 antibodies 3 months after infection. Analyses after 5 months of infection showed that only 17.2 % of people still had anti-RBD-Spike antibodies, however, most volunteers had some degree of cellular immune response. The strategy of letting people become naturally infected with SARS-CoV-2 to achieve herd immunity is flawed, and the first contact with the virus may not generate enough immunogenic stimulus to prevent a possible second infection.
Keywords: SARS-CoV-2; cell immunity; herd immunity; humoral immunity.